ReviewWorld journal of gastroenterology2020
Update on quinolone-containing rescue therapies for
Review in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05863858 (High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Third-line and rescue therapy for refractoryWorld journal of gastroenterology · 2023Pooled it
- Pooled it
- Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression.Journal of gastroenterology · 2026Review
- Helicobacter pylori Management in Older Adults: Current Perspectives From Japan.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- TargetingJournal of clinical biochemistry and nutrition · 2025Article
- Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection.BMC gastroenterology · 2025Article
- Article
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study.Medicine · 2024Article
- Tailored Therapy Using Bismuth Add-on Standard Triple Therapy vs. Concomitant Therapy: A First-line Regimen forThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Primary Antibiotic Resistance ofPathogens (Basel, Switzerland) · 2022Review
- Therapeutic Potential of Sitafloxacin as a New Drug Candidate forAntibiotics (Basel, Switzerland) · 2021Article
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?United European gastroenterology journal · 2021Article
- Clinical features of cardiac nodularity-like appearance induced byWorld journal of gastroenterology · 2020Article
- BestAntibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Third generation of quinolones, such as levofloxacin and moxifloxacin, -containing regimens are often used in second-line or rescue treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.